Shandong Buchang Pharmaceuticals Co., Ltd. (SHA:603858)
China
· Delayed Price · Currency is CNY 16.59
-0.13 (-0.78%)
At close: Mar 9, 2026
SHA:603858 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 10,928 | 10,974 | 13,229 | 14,942 | 15,755 | 15,983 | Upgrade
|
| Other Revenue | 32.06 | 32.06 | 16.62 | 9.62 | 7.36 | 23.24 | Upgrade
|
| Revenue | 10,960 | 11,006 | 13,245 | 14,951 | 15,763 | 16,007 | Upgrade
|
| Revenue Growth (YoY) | -6.93% | -16.91% | -11.41% | -5.15% | -1.52% | 12.29% | Upgrade
|
| Cost of Revenue | 4,093 | 4,552 | 4,321 | 4,268 | 4,134 | 3,739 | Upgrade
|
| Gross Profit | 6,867 | 6,454 | 8,924 | 10,683 | 11,629 | 12,268 | Upgrade
|
| Selling, General & Admin | 5,373 | 5,333 | 7,365 | 8,387 | 9,237 | 9,212 | Upgrade
|
| Research & Development | 318.83 | 345.41 | 335.08 | 284.12 | 408.6 | 533.42 | Upgrade
|
| Other Operating Expenses | 116.44 | 120.01 | 181.03 | 232.07 | 226.9 | 234.55 | Upgrade
|
| Operating Expenses | 5,769 | 5,773 | 7,889 | 8,907 | 9,888 | 9,981 | Upgrade
|
| Operating Income | 1,098 | 680.71 | 1,035 | 1,776 | 1,741 | 2,287 | Upgrade
|
| Interest Expense | -123.4 | -129.59 | -109.93 | -135.1 | -167.29 | -145.05 | Upgrade
|
| Interest & Investment Income | 17.04 | 20.55 | 40.12 | 22.61 | 41.34 | 32.9 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.19 | 0.19 | 0.08 | 0.45 | -0.12 | 0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | 89.11 | -3.88 | -47.33 | -11.43 | -6.73 | 9.5 | Upgrade
|
| EBT Excluding Unusual Items | 1,081 | 567.97 | 918.42 | 1,652 | 1,608 | 2,184 | Upgrade
|
| Impairment of Goodwill | -853.03 | -853.03 | -598.03 | -2,943 | -10.15 | -0.24 | Upgrade
|
| Gain (Loss) on Sale of Investments | 14.34 | -0.15 | -2.36 | -56.79 | -60 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.9 | -1.62 | -2.47 | -0.66 | -0.59 | -0.54 | Upgrade
|
| Asset Writedown | 19.45 | -0.25 | -0.3 | - | - | - | Upgrade
|
| Other Unusual Items | -106.32 | -78.21 | 79.3 | 88.51 | 176.49 | 177.25 | Upgrade
|
| Pretax Income | 153.44 | -365.29 | 394.56 | -1,259 | 1,714 | 2,361 | Upgrade
|
| Income Tax Expense | 282.58 | 337.1 | 242.69 | 331.59 | 478.29 | 517.55 | Upgrade
|
| Earnings From Continuing Operations | -129.14 | -702.39 | 151.87 | -1,591 | 1,235 | 1,843 | Upgrade
|
| Minority Interest in Earnings | 130.8 | 148.6 | 167.11 | 61.24 | 53.84 | 17.75 | Upgrade
|
| Net Income | 1.66 | -553.8 | 318.97 | -1,530 | 1,289 | 1,861 | Upgrade
|
| Net Income to Common | 1.66 | -553.8 | 318.97 | -1,530 | 1,289 | 1,861 | Upgrade
|
| Net Income Growth | - | - | - | - | -30.72% | -4.37% | Upgrade
|
| Shares Outstanding (Basic) | 1,060 | 1,084 | 1,106 | 1,106 | 1,106 | 1,106 | Upgrade
|
| Shares Outstanding (Diluted) | 1,060 | 1,084 | 1,106 | 1,106 | 1,106 | 1,106 | Upgrade
|
| Shares Change (YoY) | -3.15% | -2.01% | -0.00% | -0.01% | 0.01% | -0.87% | Upgrade
|
| EPS (Basic) | 0.00 | -0.51 | 0.29 | -1.38 | 1.17 | 1.68 | Upgrade
|
| EPS (Diluted) | 0.00 | -0.51 | 0.29 | -1.38 | 1.17 | 1.68 | Upgrade
|
| EPS Growth | - | - | - | - | -30.72% | -3.54% | Upgrade
|
| Free Cash Flow | 959.86 | 742.96 | -725.52 | 2,212 | 886.98 | 1,422 | Upgrade
|
| Free Cash Flow Per Share | 0.91 | 0.69 | -0.66 | 2.00 | 0.80 | 1.29 | Upgrade
|
| Dividend Per Share | 0.390 | - | 0.126 | 0.960 | 0.360 | 0.526 | Upgrade
|
| Dividend Growth | 209.52% | - | -86.88% | 166.67% | -31.56% | -67.41% | Upgrade
|
| Gross Margin | 62.65% | 58.64% | 67.38% | 71.45% | 73.77% | 76.64% | Upgrade
|
| Operating Margin | 10.02% | 6.19% | 7.82% | 11.88% | 11.04% | 14.29% | Upgrade
|
| Profit Margin | 0.01% | -5.03% | 2.41% | -10.23% | 8.18% | 11.63% | Upgrade
|
| Free Cash Flow Margin | 8.76% | 6.75% | -5.48% | 14.80% | 5.63% | 8.89% | Upgrade
|
| EBITDA | 1,426 | 1,115 | 1,612 | 2,256 | 2,233 | 2,711 | Upgrade
|
| EBITDA Margin | 13.01% | 10.13% | 12.17% | 15.09% | 14.17% | 16.94% | Upgrade
|
| D&A For EBITDA | 328.36 | 434.7 | 576.49 | 479.96 | 492.39 | 424.55 | Upgrade
|
| EBIT | 1,098 | 680.71 | 1,035 | 1,776 | 1,741 | 2,287 | Upgrade
|
| EBIT Margin | 10.02% | 6.19% | 7.82% | 11.88% | 11.04% | 14.29% | Upgrade
|
| Effective Tax Rate | 184.16% | - | 61.51% | - | 27.91% | 21.92% | Upgrade
|
| Revenue as Reported | 10,960 | 11,006 | 13,245 | 14,951 | 15,763 | 16,007 | Upgrade
|
| Advertising Expenses | - | 27.08 | 41.38 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.